Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Fig. 1

Cumulative rates of development immune-related adverse events (irAEs) in patients with malignancy who were treated with immune checkpoint inhibitors. a Cumulative development rates with any grade and grade ≥ 3 of irAEs. b Cumulative development rates with grade ≥ 3 of irAEs according to the regimen

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us